At what enterprise value was PROTEOR acquired in 2021?

You can find the full valuation details of PROTEOR on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.4x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of PROTEOR when it was acquired by ARDIAN / BNP PARIBAS DEVELOPPEMENT?

The exact EV/EBITDA multiple for PROTEOR is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.4x. Join our community for free to access full valuation data and industry trends.

When was PROTEOR acquired by ARDIAN / BNP PARIBAS DEVELOPPEMENT?

PROTEOR was acquired by ARDIAN / BNP PARIBAS DEVELOPPEMENT in 2021.

What was the revenue of PROTEOR at the time of the deal?

The revenue of PROTEOR at the time of the deal is estimated to be in the range of 100M - 200M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of PROTEOR during the acquisition?

PROTEOR's EBITDA is estimated to be in the range of 5M - 25M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the PROTEOR acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the PROTEOR deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.ardian.com/fr/communiques-de-presse/proteor-leader-francais-de-lorthopedie-externe-accueille-ardian-et-bnp#:~:text=Paris%2C%2013%20janvier%2C%202021%20%E2%80%93,partenaires%20pour%20l'accompagner%20dans

← DATABASE

Home Database Healthcare & PharmaPROTEOR

01/2021

PROTEOR acquired by ARDIAN & BNP PARIBAS DEVELOPPEMENT

FRANCE Life Sciences / MedTech / Implants & Prosthetics REV 100M - 200M EUR

Context

For the first time since its founding in 1913, Proteor has opened its capital to institutional investors through a primary Owner Buy-Out (OBO). Ardian Growth and BNP Paribas Développement have injected €24 million (a mix of convertible bonds and equity) to support the group's next phase of expansion. The founding Archambeaud family maintains clear majority control of the group. The strategic rationale for this primary round is to provide Proteor with the financial firepower to execute major international build-ups, specifically the $17 million acquisition of the US-based assets of Freedom Innovations. This deal transforms Proteor into a global player in the high-tech prosthetics market, integrating advanced micro-processor technologies and strengthening its footprint in North America.

PROTEOR, which reported an EBITDA margin of LOGIN in 2020, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.4x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 1913, PROTEOR is a world-class leader in the orthotics and prosthetics (O&P) market. The group specializes in high-tech orthopedic components (microprocessor knees, bionic feet) and custom-made medical devices. It operates a dual model combining manufacturing (R&D/Sales) and a large network of specialized care centers in France.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2020

2019

Other operations with PROTEOR

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
09/2025	CREDIT MUTUEL EQUITY / EURAZEO / BPIFRANCE / BNP PARIBAS DEVELOPPEMENT	PROTEOR	FRANCE	Life Sciences	Proteor has orchestrated a secondary Owner Buy-Out (OBO Bis). The transaction allows Ardian Growth to exit its minority position, which it held since the primary OBO in 2021, realizing a return of approximately 3x money. The founding Archambeaud family remains the majority shareholder, continuing its 4th-generation leadership. The strategic rationale for this new round is to consolidate Proteor’s industrial activity and fund future international acquisitions, building on the successful integration of Freedom Innovations in the USA. The deal was supported by a diverse pool of national and regional banks providing senior debt. This partnership aims to strengthen Proteor’s position as a global integrated player, balancing its manufacturing expertise with its extensive network of orthopedic centers amidst a consolidating global market.

REFERENCES

Revenue range: 100M - 200M EUR

EBITDA range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of PROTEOR by ARDIAN / BNP PARIBAS DEVELOPPEMENT are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Target: proteor

Acquirer: ardian / bnp paribas developpement